Delving into the Latest Updates on Bimekizumab with Synapse

Psoriasis is a chronic inflammatory condition driven by a complex interplay between heritable and microenvironmental factors. Genome-wide heritability for psoriasis (PsO) is estimated at up to 50%. Although bearing genetic susceptibility at birth, most patients will remain disease free for years until an exposomal trigger activates the immunological pathway that leads to the first disease flare. In rare patients, the first flare is an isolated event, but in most patients it will evolve into a chronically relapsing-remitting disease characterized by lasting lesions and recurrent flares. Primary objective is to compare efficacy of bimekizumab versus topical corticosteroids on psoriasis clinical disease activity, assessed by PGA, at week 16 and week 24.
Patients will be randomized 1:1 to receive either 320mg bimekizumab at weeks 0 (W0), W4, W8 and W12, or clobetasol ointment for 2 to 4 weeks until complete clearance of the lesion. After a maximum of 4 weeks topical clobetasol will be applied twice weekly on the site of lesion until week 16 then stopped. Patients will not receive active treatment between week 16-24. Between week 24-96 patients that flare can receive continuous topical clobetasol if needed. These patients will be considered non-responders at subsequent timepoints for the main analysis. If the patients worsen their psoriasis under the treatments given during the study and progress to moderate or severe psoriasis (PASI 10 and above) they will end their participation to the study to receive a treatment adapted to the new severity of their psoriasis. The patients will be referred to their dermatologist to receive the actual standard of care adapted to their new condition.
During the study, the following assessments will be performed and samples will be collected

Start Date01 Jun 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nice

NCT06888193

/ RecruitingPhase 1

A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.

Start Date15 Jun 2025

Sponsor / Collaborator

UCB Biopharma SRL

NCT06921850

/ RecruitingPhase 3

A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa

The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)

Start Date07 Apr 2025

Sponsor / Collaborator

UCB Biopharma SRL

100 Clinical Results associated with Bimekizumab

Login to view more data

100 Translational Medicine associated with Bimekizumab

Login to view more data

100 Patents (Medical) associated with Bimekizumab

Login to view more data

309

Literatures (Medical) associated with Bimekizumab

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics

Article

Author: Loconsole, F. ; Bianchi, L. ; Gaeta Shumak, R. ; Mortato, E. ; Campione, E. ; Rivieccio, Antonia ; Lanna, C. ; Borselli, C. ; Artosi, F. ; Lambiase, S. ; Compagnucci, I.

PURPOSE:

Psoriasis is a chronic, immune-mediated inflammatory skin condition marked by erythematous, scaly plaques. This retrospective observational study evaluated the long-term efficacy and safety of bimekizumab, a dual IL-17A and IL-17F inhibitor, in treating moderate to severe plaque psoriasis in 56 patients across two dermatology clinics in Italy.

MATERIALS AND METHODS:

Adult participants with a baseline Psoriasis Area and Severity Index (PASI) >10, or <10 with sensitive area involvement, were followed for 16 to 52 weeks. Clinical outcomes were measured by PASI 75, 90, and 100 responses and Dermatology Life Quality Index (DLQI) scores at 4, 16, 36, and 52 weeks.

RESULTS:

At week 16, 97.5% of patients achieved PASI 75, 76.7% reached PASI 90, and 66% attained PASI 100. By week 52, 91.5% achieved PASI 90 and 85.1% reached PASI 100, with 95.7% reporting a Dermatology Life Quality Index (DLQI) score of 0 or 1, indicating minimal impact on daily life. The study found similar efficacy across bio-naïve and bio-experienced groups, and between normal-weight and obese patients, without statistically significant differences. The safety profile was consistent with previous trials, with oral candidiasis as the most frequent adverse event (21%).

CONCLUSIONS:

These findings support the efficacy and tolerability of bimekizumab for long-term psoriasis management.

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Bimekizumab as-needed dosing in patients with psoriasis: a case series

Article

Author: Blauvelt, Andrew ; Berna-Rico, Emilio ; Jaén, Pedro ; González-Cantero, Álvaro ; Abbad-Jaime De Aragón, Carlota

INTRODUCTION:

Despite significant advances in psoriasis treatment, off-label dosing studies of psoriasis biologic therapies are limited.

MATERIALS AND METHODS:

In this retrospective case series, medical records from 28 patients with moderate-to-severe psoriasis treated with bimekizumab during 64-week period from May 2023 to October 2024 at the Psoriasis Unit of the Grupo Jaen (Madrid, Spain), were evaluated. Patients were managed with an off-label, as-needed, dosing strategy, with all patients initially receiving two 320 mg doses of bimekizumab at Weeks 0 and 4; subsequent doses were administered only if a given patient dropped below a PASI90 response. Primary outcome was the percentage of patients that achieved and maintained optimal skin control over time, defined as achieving a PASI90 response.

RESULTS:

Twenty-seven out of the 28 patients achieved a PASI90 response after the first two bimekizumab doses, and all maintained PASI90 responses with as-needed dosing over time. One patient achieved PASI90 after a single dose of bimekizumab, and voluntarily decided not to receive a second dose. No adverse events were observed.

CONCLUSIONS:

Larger prospective studies comparing efficacy and safety of this off-label, as needed, bimekizumab dosing regimen with standard on-label dosing are necessary to corroborate these findings.

01 Jun 2025·JAAD international

Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis

Article

Author: Hashemi, Kimberly ; Vazquez-Machado, Maria ; LaChance, Avery H ; Loranger, Nicole ; Elshaboury, Soha ; Zangenah, Nikki

131

News (Medical) associated with Bimekizumab

02 Jun 2025

·www.einpresswire.com

New Wave of Therapies for Hidradenitis Suppurativa Targets Deeper Efficacy and Patient-Centered Innovation | CI Insights

The hidradenitis suppurativa market is evolving as developers target novel immune pathways and next-gen therapies for improved patient outcomes. With emerging therapies targeting novel pathways and demanding higher clinical benchmarks, hidradenitis suppurativa is entering a new era of patient-centric innovation.” — DataM Intelligence AUSTIN, TX, UNITED STATES, June 2, 2025 / EINPresswire.com / -- New Wave of Therapies for Hidradenitis Suppurativa Targets Deeper Efficacy and Patient-Centered Innovation Hidradenitis suppurativa (HS) -a painful, chronic skin disease marked by recurring nodules, abscesses, and scarring-is finally seeing the long-overdue attention of the global biopharmaceutical industry. Affecting over 3 million people worldwide, including more than 300,000 in the U.S. alone, HS has historically been underserved, with limited treatment options and a high burden on patients’ quality of life. But the competitive landscape is shifting. In recent years, regulatory approvals for adalimumab (Humira), secukinumab (Cosentyx), and bimekizumab (Bimzelx) have laid the foundation for targeted biologics in HS. Now, next-generation programs are aiming higher-not only to match but exceed these standards by targeting deeper lesion resolution, faster onset, and more sustainable relief across difficult-to-treat patient populations. Book Your Free CI Consultation Call: https://www.datamintelligence.com/strategic-insights/hidradenitis-suppurativa Pipeline Progress: A Surge of Innovation The HS pipeline now includes therapies across a range of modalities and mechanisms of action, with a dozen late-stage candidates aiming for FDA approval within the next 3–5 years. Standouts include: - Lutikizumab, an IL-1α/β inhibitor targeting upstream inflammation, currently advancing through mid-to-late-stage trials. - Remibrutinib, a BTK inhibitor that promises a novel oral route of administration and potentially superior safety. - Spesolimab, an IL-36 antagonist, demonstrating promise in early inflammatory control and tunnel reduction. These novel mechanisms aim to differentiate themselves from the crowded TNF and IL-17 biologic space. Their entry could represent a turning point for HS management, especially for patients who have not responded to current therapies. Best-in-Class & Oral Contenders Meanwhile, bimekizumab and sonelokimab are aiming for best-in-class efficacy in the IL-17 category, leveraging dual isoform targeting and nanobody fusion technology. In parallel, oral agents like upadacitinib (a JAK1 inhibitor) and povorcitinib are carving out space as daily, patient-friendly options-but will need to overcome safety concerns associated with JAK inhibition. Notably, new clinical trial designs are setting more ambitious targets. Where earlier studies relied on HiSCR50-a 50% reduction in abscesses and nodules-emerging candidates are pushing for HiSCR75 or even HiSCR100, along with tunnel resolution and long-term durability. This represents a critical shift toward outcomes that matter most to patients. Target Opportunity Profile (TOP): What Success Looks Like in HS As the pipeline matures, a clear Target Opportunity Profile (TOP) has emerged-outlining what a successful HS therapy must deliver: - Superior Efficacy: Achieving HiSCR75 or higher at 12 weeks and maintaining benefits through one year. - Novel Mechanisms: Targeting IL-36, BTK, or inflammasome pathways to modulate inflammation more precisely. - Patient-Centered Design: Oral or monthly SC administration preferred; minimal systemic side effects. - Subgroup Impact: Proven benefit in Hurley Stage II/III disease, tunnel clearance, adolescent patients, and post-biologic failures. - Value-Driven Access: Demonstrated pharmacoeconomic benefit, such as reducing surgeries, ER visits, or work loss. Emerging therapies that meet these benchmarks will be best positioned to disrupt the market and shift treatment paradigms, particularly as payers, regulators, and prescribers seek options that not only work but are sustainable and accessible for patients long-term. Download Free CI Sample Report: https://www.datamintelligence.com/strategic-insights/sample/hidradenitis-suppurativa Strategic Outlook The race to redefine HS treatment is heating up. With increasing trial innovation, expanded patient stratification, and a focus on truly disease-modifying outcomes, developers are moving beyond the “me-too” biologics of yesterday. The field is ripe for disruption-and the next generation of HS therapies may finally offer the transformative relief patients have long awaited. Read More CI Reports by DataM Intelligence: 1. Nurofibromatosis Type 1 | Competitive Intelligence 2. Gauchers Disease | Competitive Intelligence Sai Kiran DataM Intelligence 4market Research LLP 877-441-4866 email us here Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

21 May 2025

·pipelinereview.com

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to three times per year in psoriasis, a significant improvement over standard of care MENLO PARK, CA, USA I May 20, 2025 I Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-002, the Company’s novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-17A and IL-17F (IL-17A/F). “With both ORKA-001 and ORKA-002 now in human trials, we are moving quickly to demonstrate the clinical differentiation of both assets,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka. “Bimekizumab is launching extremely well as IL-17A/F has emerged as superior to IL-17A inhibition in several important indications. Uniquely, we could have the best targeting approaches for both IL-23p19 and IL-17A/F, potentially allowing us to offer the ideal regimen to patients through our ORKA-001 and -002 monotherapies and our ORKA-021 sequential combination.” The ORKA-002 Phase 1 trial is a double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability and pharmacokinetics (PK) of ORKA-002 in approximately 24 healthy volunteers across three subcutaneous dose cohorts. Oruka expects to share interim data from this study around year end 2025. Pending data from the Phase 1 trial, Oruka plans to initiate a Phase 2 study of ORKA-002 in moderate-to-severe psoriasis in the first half of 2026. The planned study design will evaluate the safety and efficacy of multiple dose levels and regimens of ORKA-002, with a primary endpoint of PASI 100 at week 16. “ORKA-002 has the opportunity to become the best antibody in the IL-17 class, which is preferred when treating psoriasis with joint involvement or recalcitrant skin disease, as well as psoriatic arthritis, hidradenitis suppurativa, and beyond,” said Joana Goncalves, MBChB, Chief Medical Officer of Oruka. “With this program now in the clinic, we are one step closer to our goal of offering the most possible freedom from disease to patients with psoriasis and other conditions.” About ORKA-002 ORKA-002 is a novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-17A/F. Dual inhibition of both IL-17A and IL-17F has shown superior efficacy compared to IL-17A inhibition alone in psoriasis (PsO) and other indications, as shown by the performance of Bimzelx (bimekizumab) compared to Cosentyx (secukinumab) and Taltz (ixekizumab) in Phase 3 trials. These therapies all utilize monthly maintenance dosing in PsO and psoriatic arthritis (PsA), except Bimzelx in PsO patients weighing <120 kg, where Q8W maintenance dosing is recommended. In contrast, ORKA-002 has the potential to be dosed just two to three times per year in PsO and PsA, which we believe could allow ORKA-002 to become the leading therapy in the IL-17 class. Data from studies in non-human primates and other preclinical assays show that ORKA-002 binds to a similar epitope with similar affinity as bimekizumab and has a significantly extended half-life over three times longer than bimekizumab. About Oruka Therapeutics Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn. SOURCE: Oruka Therapeutics

Phase 1Phase 3Clinical Result

20 May 2025

·www.fiercepharma.com

As Eli Lilly outperforms Novo in market, it also replaces its rival in annual IDEA Innovation rankings

Eli Lilly and AstraZeneca landed at the top of IDEA Pharma's annual Innovation Index and Invention Index rankings, respectively. As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index, which ranks (PDF) the most transformative companies in the biopharma industry.While Lilly advanced from fourth place in 2024 to the top spot this year, it has supplanted last year's champion Novo, which tumbled all the way to eighth place. It’s a familiar perch for Lilly, which earned IDEA’s No. 1 slot in 2019 and 2021.This is the 14th year that IDEA, a pharmaceutical industry consulting firm based in London, has conducted the analysis. In 2019, IDEA added an annual Invention Index, which was topped by AstraZeneca for the third time in the last four years.In conducting its Innovation ranking, IDEA asks two questions: Who in the industry is at the forefront of innovation and what are they doing to achieve this? Additionally, if two biopharma companies were given the same molecule in early phase, which would better develop and launch it and why?In ranking Lilly No. 1, IDEA cited the FDA approvals of obesity drug Zepbound for obstructive sleep apnea, Kisunla for Alzheimer’s disease and Ebglyss for atopic dermatitis, each of which came in the second half of 2024.IDEA also recognized Lilly’s $3.2 billion buyout of Morphic to expand its immunology portfolio and its creation of the LillyDirect platform, which “reflects the company’s commitment to improving patient access and affordability by streamlining therapy delivery and reducing insulin costs.”On the flip side, in addition to falling into No. 8 on the Innovation Index, Novo plummeted to last place in the Invention Index. In both categories, IDEA ranks the industry’s top 30 companies.Novo’s declining fortunes are reflected in a market cap slide from $640 billion in July of last year to its present figure of $293 billion. Last week, the company announced the departure of eight-year CEO Lars Fruergaard Jørgensen. Also receiving high marks in the Innovation rankings were No. 2 Merck, which jumped from the 10th slot largely because of the continued progression of the development of megablockbuster Keytruda. Third-place AZ and fourth-place Roche rose from Nos. 7 and 8, respectively, while Pfizer, which claimed consecutive titles in 2022 and 2023 for its rapid development of COVID-19 products, came in at No. 5. Also making notable jumps were No. 6 Regeneron, from 15th place, No. 7 UCB, which vaulted from outside of the top 20, and No. 10 Novartis, which was up from 17th place.UCB’s leap was fueled by “significant advancements in immunology, neurology and rare diseases,” IDEA wrote, citing advancements with Bimzelx in inflammatory conditions. "With a pipeline that spans high-need therapeutic areas, UCB has re-established itself as a resilient and innovative player, leveraging differentiated biologics and cutting-edge research to address unmet patient needs,” IDEA CEO Mike Rea said in a release.While IDEA’s Innovation Index measures how well companies perform in bringing new medicines to market and commercializing them, its Invention Index examines the breadth and depth of novel agents currently being developed within the top 30 pharma pipelines. The Invention Index provides a more forward-looking view of who is developing medicines that matter, embracing science and innovations in R&D. AZ’s recent dominance of the category is owed to its deep portfolio across several disease areas, including oncology, evidenced by the success and additional potential of blockbusters Tagrisso, Imfinzi and Enhertu across multiple cancer types.AZ replaced Johnson & Johnson in the top spot, with J&J falling to second place this year, one notch in front of Moderna. As they did in the Innovation Index, Roche and Regeneron also made significant leaps, from No. 17 and No. 8, respectively, last year, to tie for fourth place. Jumping from the teens into the top 10 were No. 8 GSK, as well as BeiGene and Boehringer Ingelheim, which tied for 10th place. Others in the Invention Index top 10 were No. 6 Lilly, No. 7 Merck and No. 9 Pfizer.In addition to Novo placing last in the Invention Index, others who performed poorly in the rankings were Merck KGaA, which placed No. 30 in Innovation and No. 26 in Invention. Takeda also was in the bottom five in both categories. Bayer, Biogen, AbbVie and Otsuka were in the bottom 10 in both categories.

AcquisitionDrug Approval

100 Deals associated with Bimekizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11550	Bimekizumab	-	DB12917

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hidradenitis Suppurativa	European Union	UCB Pharma SA	30 Apr 2024
Hidradenitis Suppurativa	Iceland	UCB Pharma SA	30 Apr 2024
Hidradenitis Suppurativa	Liechtenstein	UCB Pharma SA	30 Apr 2024
Hidradenitis Suppurativa	Norway	UCB Pharma SA	30 Apr 2024
Ankylosing Spondylitis	European Union	UCB Pharma SA	15 Jun 2023
Ankylosing Spondylitis	Iceland	UCB Pharma SA	15 Jun 2023
Ankylosing Spondylitis	Liechtenstein	UCB Pharma SA	15 Jun 2023
Ankylosing Spondylitis	Norway	UCB Pharma SA	15 Jun 2023
Axial Spondyloarthritis	European Union	UCB Pharma SA	15 Jun 2023
Axial Spondyloarthritis	Iceland	UCB Pharma SA	15 Jun 2023
Axial Spondyloarthritis	Liechtenstein	UCB Pharma SA	15 Jun 2023
Axial Spondyloarthritis	Norway	UCB Pharma SA	15 Jun 2023
Non-radiographic axial spondyloarthritis	European Union	UCB Pharma SA	15 Jun 2023
Non-radiographic axial spondyloarthritis	Iceland	UCB Pharma SA	15 Jun 2023
Non-radiographic axial spondyloarthritis	Liechtenstein	UCB Pharma SA	15 Jun 2023
Non-radiographic axial spondyloarthritis	Norway	UCB Pharma SA	15 Jun 2023
Erythrodermic psoriasis	Japan	UCB Japan Co. Ltd.	20 Jan 2022
Psoriasis vulgaris	Japan	UCB Japan Co. Ltd.	20 Jan 2022
Pustular psoriasis	Japan	UCB Japan Co. Ltd.	20 Jan 2022
Arthritis, Psoriatic	European Union	UCB Pharma SA	20 Aug 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Enthesitis-Related Arthritis	Phase 3	Canada	UCB Biopharma SRL	11 Mar 2025
Enthesitis-Related Arthritis	Phase 3	France	UCB Biopharma SRL	11 Mar 2025
Enthesitis-Related Arthritis	Phase 3	Germany	UCB Biopharma SRL	11 Mar 2025
Enthesitis-Related Arthritis	Phase 3	Poland	UCB Biopharma SRL	11 Mar 2025
Enthesitis-Related Arthritis	Phase 3	Spain	UCB Biopharma SRL	11 Mar 2025
Enthesitis-Related Arthritis	Phase 3	United Kingdom	UCB Biopharma SRL	11 Mar 2025
Juvenile Idiopathic Arthritis	Phase 3	Canada	UCB Biopharma SRL	11 Mar 2025
Juvenile Idiopathic Arthritis	Phase 3	France	UCB Biopharma SRL	11 Mar 2025
Juvenile Idiopathic Arthritis	Phase 3	Germany	UCB Biopharma SRL	11 Mar 2025
Juvenile Idiopathic Arthritis	Phase 3	Poland	UCB Biopharma SRL	11 Mar 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04255862 (CTgov)	Phase 1	-	71	bimekizumab (Bimekizumab-SS-2mL (Test 1))	jwmggherkm(piafyrtima) = cbjrleulln atvmpbrahq (xprilkbmxm, 34.2) View more	-	10 Apr 2025
				Bimekizumab-SS (Bimekizumab-SS-2x1mL (Reference 1))	jwmggherkm(piafyrtima) = uojbsfcqcb atvmpbrahq (xprilkbmxm, 31.3) View more
NCT05292131 (CTgov)	Phase 1	-	121	Bimekizumab (Bimekizumab-AI-2mL (Test))	lfulcgxxjn(nexcjczcsc) = battyuybrc bspbogmeil (ewgvhhjdie, uqvnxxndks - zwupygsgeb) View more	-	10 Apr 2025
				Bimekizumab (Bimekizumab-AI-2x1mL (Reference))	lfulcgxxjn(nexcjczcsc) = ajmaoaxbhw bspbogmeil (ewgvhhjdie, oqmvwzlulj - zuxlxnqbjk) View more
pooled results from integrated phase IIb/III clinical studies (Pubmed \| RMD Open)	Phase 2/3	Arthritis, Psoriatic \| Axial Spondyloarthritis	-	Bimekizumab 160 mg every 4 weeks	smpbknmaxg(whbyifsarq) = EAIR/100 PY of nasopharyngitis was 8.2 in axSpA and 7.7 in PsA rhbkcfewcc (kxbufgzunh ) View more	Positive	01 Apr 2025
NCT03766685 (Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Chronic large plaque psoriasis	-	Bimekizumab 320 mg via 2 mL Safety Syringe	avfnrbocva(zelvnbrwbi) = all adverse device effects reported were mild and did not lead to discontinuation qvtbrwkjiq (fezhtvrvty ) View more	-	29 Mar 2025
				Bimekizumab 320 mg via Auto-injector
NCT04242446 (BE HEARD I, CTgov)	Phase 3	Hidradenitis Suppurativa	505	placebo (Placebo)	svcujsvsxh = wpdhcysoyc hmzhjfybel (fxliuhhkqu, keqxgycswp - hkqnwxcsmt) View more	-	09 Jan 2025
				BKZ (BKZ Dosing Regimen 1)	svcujsvsxh = vmzacfpejx hmzhjfybel (fxliuhhkqu, pvshqwnzzg - swtrnfonws) View more
BE AGILE (Pubmed \| RMD Open)	Phase 2	Ankylosing Spondylitis \| Axial Spondyloarthritis	-	Bimekizumab 160 mg every 4 weeks	zocjxpmzho(mfwihtpnbf) = hoareqswra dhrkatuqjy (clikipyyam ) View more	Positive	01 Jan 2025
NCT03598790 (BE BRIGHT, CTgov)	Phase 3	Plaque psoriasis	1,353	BKZ (Cohort A: BKZ 320 mg Q8W)	fxrqojdbwp = dejccwgpwy gtthezsmzc (jgumcupmue, stckocvwuy - mlmvefujxt) View more	-	06 Dec 2024
				BKZ (Cohort A: BKZ 320 mg Q4W)	fxrqojdbwp = cdxsycgjmx gtthezsmzc (jgumcupmue, dtivzrxech - jkqduybehw) View more
NCT04242498 (BE HEARD II, CTgov)	Phase 3	Hidradenitis Suppurativa	509	placebo (Placebo)	xiexmcrcld = sacaiggwms dnvyucbecu (alhuoomjov, tqbtnxtwjh - nilbqcgwlq) View more	-	05 Dec 2024
				BKZ (BKZ Dosing Regimen 1)	xiexmcrcld = rdzsbkyfmg dnvyucbecu (alhuoomjov, puumjkcocj - fselelzqra) View more
NCT03412747 \| NCT03370133 \| NCT03536884 \| NCT03410992 \| NCT03598790 (BE VIVID \| BE READY \| BE SURE \| BE BRIGHT \| BE RADIANT, Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Psoriasis	1,107	Bimekizumab	clowcbpmxz(jjiuitiiki) = carjksqltq ukosqoiwxg (gtjwvvafyu ) View more	Positive	01 Dec 2024
Pubmed \| Ann Rheum Dis	Not Applicable	Axial Spondyloarthritis	-	Bimekizumab 160 mg	xdfxxdkhtl(ggaziivizk) = hkfaibfeyf ioirwmdnbb (axjdsmnhlx )	-	01 Dec 2024
				Placebo	xdfxxdkhtl(ggaziivizk) = ioyxkixegr ioirwmdnbb (axjdsmnhlx )

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Bimekizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation